Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Head & Neck 2Breast 2Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Melanoma 9Triple Negative Breast Neoplasms 8Lung Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Neoplasms 3Mesothelioma 3Lymphoma 3Head and Neck Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2NSCLC 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2

Interventions

pembrolizumab 9Nivolumab 4Carboplatin 4spartalizumab 2durvalumab 2Paclitaxel 2Immunohistochemistry 2Gemcitabine 2Cisplatin 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tremelimumab 1ribociclib 1regorafenib 1obinutuzumab 1naptumomab estafenatox 1liposomal doxorubicin 1enzalutamide 1atezolizumab 1aflibercept 1abiraterone 1SGN-LIV1A 1Ritonavir 1Remote Patient Monitoring 1Polymerase Chain Reaction 1Oxaliplatin 1NEO212 1Mass Spectrometry 1Lopinavir 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × spartalizumab × Thoracic × Clear all
NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis

Phase 1 Terminated
122 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡